Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?

被引：1

作者：

Seo, Ji A. ^{[1
]}

机构：

[1] Korea Univ, Coll Med, Ansan Hosp, Div Endocrinol & Metab,Dept Internal Med, 123 Jeokgeum Ro, Ansan 15355, South Korea

来源：

JOURNAL OF OBESITY & METABOLIC SYNDROME | 2018年 / 27卷 / 01期

关键词：

D O I：

10.7570/jomes.2018.27.1.1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1 / 3

页数：3

共 20 条

[1] Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018 [J].

不详 .

DIABETES CARE, 2018, 41 :S65-S72

[2] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[3] Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial [J].

Baum, Aaron ;

Scarpa, Joseph ;

Bruzelius, Emilie ;

Tamler, Ronald ;

Basu, Sanjay ;

Faghmous, James .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (10) :808-815

[4] The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis [J].

Cai, Xiaoling ;

Yang, Wenjia ;

Gao, Xueying ;

Chen, Yifei ;

Zhou, Lingli ;

Zhang, Simin ;

Han, Xueyao ;

Ji, Linong .

OBESITY, 2018, 26 (01) :70-80

[5]

Cho HA, 2017, J OBES METAB SYNDR, V26, P107, DOI 10.7570/jomes.2017.26.2.107

[6] Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [J].

Dandona, Paresh ;

Mathieu, Chantai ;

Phillip, Moshe ;

Hansen, Lars ;

Griffen, Steven C. ;

Tschope, Diethelm ;

Thoren, Fredrik ;

Xu, John ;

Langkilde, Anna Maria .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11) :864-876

[7] Renal, metabolic and cardiovascular considerations of SGLT2 inhibition [J].

DeFronzo, Ralph A. ;

Norton, Luke ;

Abdul-Ghani, Muhammad .

NATURE REVIEWS NEPHROLOGY, 2017, 13 (01) :11-26

[8] Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition [J].

Ferrannini, Giulia ;

Hach, Thomas ;

Crowe, Susanne ;

Sanghvi, Arjun ;

Hall, Kevin D. ;

Ferrannini, Ele .

DIABETES CARE, 2015, 38 (09) :1730-1735

[9] CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2017 EXECUTIVE SUMMARY [J].

Garber, Alan J. ;

Abrahamson, Martin J. ;

Barzilay, Joshua I. ;

Blonde, Lawrence ;

Bloomgarden, Zachary T. ;

Bush, Michael A. ;

Dagogo-Jack, Samuel ;

DeFronzo, Ralph A. ;

Einhorn, Daniel ;

Fonseca, Vivian A. ;

Garber, Jeffrey R. ;

Garvey, W. Timothy ;

Grunberger, George ;

Handelsman, Yehuda ;

Hirsch, Irl B. ;

Jellinger, Paul S. ;

McGill, Janet B. ;

Mechanick, Jeffrey I. ;

Rosenblit, Paul D. ;

Umpierrez, Guillermo E. .

ENDOCRINE PRACTICE, 2017, 23 (02) :207-238

[10] Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes [J].

Henry, Robert R. ;

Thakkar, Payal ;

Tong, Cindy ;

Polidori, David ;

Alba, Maria .

DIABETES CARE, 2015, 38 (12) :2258-2265

← 1 2 →